GlassScriptPhysician profile
David Safar
NPI 1548344195
$1,597.95
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $590.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $559.14 | 2019-2020 | |
| Lilly USA, LLC | $175.53 | 2019-2020 | |
| Allergan, INC. | $150.40 | 2019-2020 | |
| Amgen INC. | $132.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $131.11 | 2019 | |
| Acorda Therapeutics, INC | $110.31 | 2020 | |
| Genentech USA, INC. | $107.00 | 2020 | |
| Upsher-Smith Laboratories LLC | $53.96 | 2019 | |
| Amneal Pharmaceuticals LLC | $41.82 | 2019 | |
| Zyla Life Sciences, INC. | $25.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.00 | 2019 | |
| Scilex Pharmaceuticals INC. | $23.99 | 2019-2020 | |
| Genzyme Corporation | $13.47 | 2019 | |
| Currax Pharmaceuticals LLC | $13.38 | 2020 | |
| Biogen, INC. | $12.50 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $11.86 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Safar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.